Skip to main content

Table 1 PD-1 signal inhibitors (anti–PD-1 and anti–PD-L1 antibodies) in clinical trials

From: Cancer immunotherapies targeting the PD-1 signaling pathway

Target

Agent

IgG class

Company

Approved

PD-1

nivolumab (Opdivo®, BMS-936558, MDX1106)

Human IgG4

Bristol-Meyers Squibb/Ono

MelanomaU, E, J

Lung cancerU, E, J

Kidney cancerU, J

Hodgkin’s lymphoma U, E, J

Head and neck cancer U

Urothelial cancer U

pembrolizumab (Keytruda®MK-3475, lambrolizumab)

Humanized IgG4

Merck

MelanomaU, E, J

Lung cancerU, E, J

Head and neck cancerU

pidilizumab (CT-011)

Humanized IgG1k

Cure Tech

 

AMP-224

PD-L2 IgG2a fusion protein

Amplimmune/GlaxoSmith Klein

 

AMP-514 (MEDI0680)

PD-L2 fusion protein

Amplimmune/GlaxoSmith Klein

 

PDR001

Humanized IgG4

Novartis Pharmaceuticals

 

PD-L1

BMS-936559 (MDX1105)

Human IgG4

Bristol-Meyers Squibb

 

atezolizumab (Tecentriq®, MPDL3280A)

Humanized IgG1k

Roche/Genentech

Urothelial cancerU

Lung cancerU

durvalumab (MEDI4736)

Human IgG1k

MedImmune/AstraZeneca

 

avelumab (MSB0010718C)

Human IgG1

Merck Serono/Pfizer

 
  1. All antibodies used in clinical trials as of September 1, 2016 were extracted from ClinicalTrials.gov
  2. Abbreviations: U U.S. Food and Drug Administration (FDA) approved; E European Medicines Agency (EMA) approved, J Japanese Pharmaceutical and Medical Devices Agency (PMDA) approved